Skip to main content
Sean J. Barbour on Muck Rack

Sean J. Barbour

As seen in: JAMA (The Journal of the American Medical Association), The Lancet, ASN Journals
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sean J.

Contact Sean J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy

|
By Sean J. Barbour, Jürgen Floege, Richard Lafayette
| kidney-international.org
Abstract Atacicept is a first-in-class, dual anti-B-cell Activation Factor–A Proliferation-Inducing Ligand fusion protein in clinical evaluation for treatment of IgA nephropathy. To compare efficacy and safety of atacicept versus placebo in patients with IgAN, this randomized, double-blind, placebo-controlled phase 2b clinical trial ORIGIN enrolled 116 individuals with biopsy-proven IgA nephropathy.
Open in Who Shared Issue with article?

PROTECTing the kidneys in IgA nephropathy

|
By Heather N Reich, Sean J. Barbour
| The Lancet Verified
Treatment of IgA nephropathy has traditionally focused on immunosuppression to address the pathogenesis of the disease and kidney-protective strategies, such as modulation of the renin–angiotensin system to prevent disease progression; 40–50% of patients nonetheless develop kidney failure within 10–15 years of diagnosis.The relatively long duration for progression to kidney failure has been a barrier for executing trials of novel therapies for IgA nephropathy.
Open in Who Shared Issue with article?

Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis

|
By Hannah Lomax-Browne, Sean J. Barbour, Nicholas R. Medjeral-Thomas, Jack Gisby
Abstract Background and objectives C3 glomerulopathy and idiopathic Ig-associated membranoproliferative GN are kidney diseases characterized by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of patients develop kidney failure within 10 years.
Open in Who Shared Issue with article?
See all 7 articles